Tolerx

Tolerx, Inc. is a privately held company based in Cambridge, Massachusetts. With a team of 9 employees, the company focuses on developing innovative immunotherapies for a variety of conditions. Tolerx's portfolio includes a range of drug candidates targeting type 1 diabetes, autoimmune diseases, and cancer. Their lead candidate, otelixizumab, is a targeted T cell immunotherapy currently in Phase 3 development for type 1 diabetes, with GlaxoSmithKline as a partner. They also have TRX518, a targeted T cell immunotherapy in Phase 1 development for cancer, and TRX1, an anti-CD4 antibody previously clinically evaluated for treating aberrant immune responses. In addition to their clinical candidates, Tolerx has two preclinical candidates, TRX585 and TRX385, designed to enhance immune responses and are being explored for potential use in cancer and chronic viral infections. For further information, visit Tolerx's website at tolerx.com.